医学
贫血
心力衰竭
缺铁
共病
重症监护医学
红细胞生成
内科学
缺铁性贫血
作者
Natasha Purai Arora,Jalal K. Ghali
标识
DOI:10.1016/j.hfc.2013.11.002
摘要
Anemia is a common comorbidity in patients with heart failure (HF) and is associated with poor prognosis. Iron deficiency, with or without anemia, confers increased risk of mortality and morbidity. Along with the altered iron metabolism in HF patients, inflammation creates challenges in the interpretation of laboratory parameters used to diagnose anemia in HF. Since the RED-HF trial failed to demonstrate any benefit from the use of erythropoiesis-stimulating agents (ESAs) on mortality or morbidity in HF patients, ESAs are no longer considered a treatment option, although intravenous iron has potential as therapy for anemic and nonanemic HF patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI